Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation

EuroIntervention 2023;18:e-e. DOI: 10.4244/EIJ-D-22-00521

Norman Mangner
Norman Mangner1, MD; Miriam Brinkert2, MD; Lukas S. Keller3, MD; Noriaki Moriyama4,5, MD; Daniel Hagemeyer6, MD; Stephan Haussig1, MD; Lisa Crusius1, MD; Richard Kobza7, MD; Mohamed Abdel-Wahab8, MD; Mika Laine4, MD; Stefan Stortecky6, MD; Thomas Pilgrim6, MD; Fabian Nietlispach9,10, MD; Frank Ruschitzka9, MD; Holger Thiele8, MD; Stefan Toggweiler7, MD; Axel Linke1, MD
1. Department of Internal Medicine and Cardiology, Heart Center Dresden, Technische Universität Dresden, Dresden, Germany; 2. Division of Cardiology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland; 3. Quebec Heart and Lung Institute, Laval University, Quebec, QC, Canada; 4. Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland; 5. Division of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan; 6. Department of Cardiology, University Hospital Bern, Bern, Switzerland; 7. Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland; 8. Department of Internal Medicine/Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany; 9. Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; 10. CardioVascular Center Zürich, Hirslanden Klinik im Park, Zürich, Switzerland

Background: One-third of patients undergoing transcatheter aortic valve implantation (TAVI) have an indication for long-term oral anticoagulation (OAC).

Aims: We aimed to investigate whether continued non-vitamin K antagonist oral anticoagulant (NOAC) therapy compared with continued vitamin K antagonist (VKA) therapy during TAVI is equally safe and effective. 

Methods: Consecutive patients on OAC with either NOAC or VKA undergoing transfemoral TAVI at five European centres were enrolled. The primary outcome measure was a composite of major/life-threatening bleeding, stroke, and all-cause mortality at 30 days.

Results: In total, 584 patients underwent TAVI under continued OAC with 294 (50.3%) patients receiving VKA and 290 (49.7%) patients receiving NOAC. At 30 days, the composite primary outcome had occurred in 51 (17.3%) versus 36 (12.4%) patients with continued VKA and with continued NOAC, respectively (odds ratio [OR] 0.68, 95% confidence interval [CI]: 0.43-1.07; p=0.092). Rates of major/life-threatening bleeding (OR 0.87, 95% CI: 0.52-1.47; p=0.606) and stroke (OR 1.02, 95% CI: 0.29-3.59; p=0.974) were not different between groups. In a multivariate Cox regression analysis, continued NOAC, compared with continued VKA, was associated with a lower risk for all-cause 1-year mortality (hazard ratio [HR] 0.61, 95% CI: 0.37-0.98; p=0.043). The analysis of the propensity score-matched cohort revealed similar results.

Conclusions: Continued NOAC compared with continued VKA during TAVI led to comparable outcomes with regard to the composite outcome measure indicating that continued OAC with both drugs is feasible. These hypothesis-generating results need to be confirmed by a dedicated randomised controlled trial.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bleedingnon-vitamin K antagonist oral anticoagulantoral anticoagulationtranscatheter aortic valve implantationvitamin K antagonist
TAVI
Read next article
Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study

Latest news